# An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

> **NCT04148287** · PHASE2 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 9 (actual)

## Conditions studied

- Candidemia
- Invasive Candidiases
- Candida Infection

## Interventions

- **DRUG:** APX001

## Key facts

- **NCT ID:** NCT04148287
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-13
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04148287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04148287, "An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04148287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*